A Drug Targeting Type 1 Narcolepsy at Its Source: Two Phase 3 Trials

Type 1 narcolepsy is driven by loss of orexin signalling, which helps regulate wakefulness and sleep. In two large randomised phase 3 trials, oveporexton — an oral, selective orexin receptor 2 agonist — was compared with placebo. After 12 weeks, treated participants stayed awake longer in formal testing, reported less daytime sleepiness and had fewer cataplexy attacks. Increased urinary frequency and transient insomnia were among the most common adverse effects. This is no longer only an experimental programme: the FDA approved oveporexton (Orzeyful) for adults with type 1 narcolepsy in the United States on 5 August 2026, although an orthopaedic surgeon or any other physician reading the report should distinguish the research results from availability, which still depends on country-specific regulatory decisions.

Source: Dauvilliers Y, Mignot E, Antczak J, et al. Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials. New England Journal of Medicine. Published online 9 September 2026. DOI: 10.1056/NEJMoa2601598; PubMed PMID 42714024. Source details and the published results were checked on 15 September 2026 against the NEJM article page and PubMed record; no correction or retraction was found in the checked records. U.S. regulatory status: FDA approval announcement, 5 August 2026.

Polish version · Back to General Medical Discoveries

Content prepared by: Tomasz Poboży - orthopaedic surgeon.